ARCHIVES

Higher Response For Gleevec In Trial; CML Patients Allowed To Switch

This article is from The Cancer Letter archive.

Vol. 25 No. 1 | January 25, 2002

Download PDF Visit The Full Archive

Related Articles

Conference Split Difference, NCI Gets $1.075 Billion

October 21, 1983

SWOG Releases RFA For Use Of Biorepository

November 12, 2010

In Brief: Terms Expire Next Year For Six NCAB Members, One On Panel; Fraumeni Preventative Oncology President

October 16, 1981

University of Pittsburgh honors breast cancer surgeon and clinical trialist Bernard Fisher with lecture and portrait.

May 13, 2005

Specialists List 15 Criteria For Choosing Health Insurance.

January 14, 2000

EORTC Screening, Pharmacology Group Focuses On CNU

January 2, 1987